Madrigal Pharmaceuticals, Inc.
MDGL
$302.17
-$0.34-0.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 107.77% | 203.47% | 290.04% | 490.91% | 399.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.44% | 45.35% | 81.13% | 104.95% | 94.08% |
| Operating Income | 47.83% | 42.82% | -18.03% | -88.01% | -94.08% |
| Income Before Tax | 50.36% | 47.04% | -8.33% | -77.12% | -91.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 50.36% | 47.04% | -8.33% | -77.12% | -91.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 50.36% | 47.04% | -8.33% | -77.12% | -91.87% |
| EBIT | 47.83% | 42.82% | -18.03% | -88.01% | -94.08% |
| EBITDA | 48.03% | 43.07% | -17.89% | -87.98% | -94.18% |
| EPS Basic | 55.06% | 52.28% | 7.96% | -51.54% | -74.47% |
| Normalized Basic EPS | 55.06% | 52.28% | 7.96% | -51.54% | -74.47% |
| EPS Diluted | 55.06% | 52.28% | 7.96% | -51.54% | -74.47% |
| Normalized Diluted EPS | 55.06% | 52.28% | 7.96% | -51.54% | -74.47% |
| Average Basic Shares Outstanding | 10.45% | 10.97% | 17.70% | 16.88% | 9.97% |
| Average Diluted Shares Outstanding | 10.45% | 10.97% | 17.70% | 16.88% | 9.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |